LONDON, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of Lumenis Pulse™ 100H and Lumenis Pulse™ 50H at the 33rd World Congress of Endourology (WCE), taking place October 1 – 4, 2015 in London, UK.
Photos accompanying this release are available at
http://www.globenewswire.com/newsroom/prs/?pkgid=36578
http://www.globenewswire.com/newsroom/prs/?pkgid=36579
The Lumenis Pulse 100H, the next generation of the VersaPulse® PowerSuite™ 100 Watt system, is a versatile and enhanced laser solution for the treatment of a wide array of clinical urologic indications including benign prostatic hyperplasia (BPH), stones, tumors or strictures, along with a range of other specialties such as general surgery, ENT, gynecology and pulmonary surgery. As a greatly effective laser system for stones and BPH, the Pulse 100H enables users to perform holmium laser enucleation of the prostate (HoLEP), the gold standard treatment for BPH, and stone dusting™.
The new system features an improved design to enhance patient safety and overall user experience. It offers a robust combination of laser parameters addressing more than 70 types of procedures, an innovative pulse reshape function for improved safety, dual pedals for improved ease of use, a hands-free ready and standby mode for minimizing cost per procedure, and a high energy per pulse of up to 3.5J with a high repetition rate of up to 50Hz.
In addition to the Pulse 100H, Lumenis will also be unveiling another key addition to the Lumenis Pulse laser family, the Pulse 50H laser system. Designed to efficiently address any type or size of stone in lithotripsy, the Pulse 50H system is a superior comprehensive solution that provides 0.2J of energy per pulse to minimize migration of even the smallest stone. Furthermore, the Pulse 50H can be later upgraded to the new Pulse 100H, allowing physicians to further leverage their investment as they grow their practice.
"The new Pulse 50H system provides all features to perform modern intra corporeal Holmium laser lithotripsy including a wide range of energy levels and frequencies," said Professor Rassweiler, M.D., Ph.D., Klinikum SLK, Heilbronn-Germany.
"With our commitment to the Endourological Society, we are proud to present two new innovative systems, the Pulse 100H and 50H, to meet the developing, dynamic market need in the field of minimally invasive urological surgery," said Tzipi Ozer-Armon, CEO of Lumenis. "The additions to the Pulse platform series signify a key improvement to our current urological solutions for HoLEP and stone dusting and empower users to achieve more than 70 types of procedures in a range of clinical specialties."
To learn more about the Lumenis Pulse 100H and 50H from leading clinical experts, please visit the company's booth # 411 during the following times:
Friday, October 2
| 14:00 | Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber |
| Speaker: Dr. Mark E. Leo, US | |
| 15:00 | HoLEP vs. TURP: A Cost Analysis |
| Speaker: Mr. Mark Cynk, UK | |
| 15:45 | Lumenis Pulse 120H and the New SlimLine 200 D/F/L for Flexible Ureteroscopy |
| Speaker: Dr. Marc Beaghler, US | |
| 16:30 | HoLEP Technique Improvements with the New Lumenis Pulse 100H |
| Speaker: Mr. Gerald Rix, UK | |
| 17:15 | HoLEP Technique Improvements with the New Lumenis Pulse 100H |
| Speaker: Mr. Gerald Rix, UK |
Saturday, October 3
| 13:00 | Lumenis' Pulse 120H and the New SlimLine 200 D/F/L for Flexible Ureteroscopy |
| Speaker: Dr. Marc Beaghler, US | |
| 13:45 | Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber |
| Speaker: Dr. Mark E. Leo, US | |
| 14:15 | HoLEP vs. TURP: A cost analysis |
| Speaker: Mr. Mark Cynk, UK | |
| 15:00 | Personal Experience of the New Lumenis Pulse 50H Used in Stone Cases |
| Speaker: Prof. Jens Rassweiler, Germany | |
| 15:45 | Lumenis Pulse 120H and the New SlimLine 200 D/F/L for Flexible Ureteroscopy |
| Speaker: Dr. Marc Beaghler, US | |
| 16:30 | Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber |
| Speaker: Dr. Mark E. Leo, US |
Sunday, October 4
| 09:00 | Lumenis Pulse 120H and the New SlimLine 200 D/F/L for Flexible Ureteroscopy |
| Speaker: Dr. Marc Beaghler, US | |
| 10:00 | Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber |
| Speaker: Dr. Mark E. Leo, US | |
| 10:45 | Personal Experience of the New Lumenis Pulse 50H Used in Stone Cases |
| Speaker: Prof. Jens Rassweiler, Germany | |
| 11:30 | Personal Experience of the New Lumenis Pulse 50H Used in Stone Cases |
| Speaker: Prof. Jens Rassweiler, Germany | |
| 13:00 | Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber |
| Speaker: Dr. Mark E. Leo, US |
* The Lumenis Pulse 100H and Lumenis Pulse 50H are not yet available in the United States.
About Lumenis
Lumenis (NASDAQ:LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
Forward-Looking Statements
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
